CAMBRIDGE, Mass., June 24,
2024 /PRNewswire/ -- Akebia Therapeutics®,
Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose
to better the lives of people impacted by kidney disease, today
announced the appointment of Erik
Ostrowski as Senior Vice President, Chief Financial Officer
and Chief Business Officer. Mr. Ostrowski is an experienced biotech
executive with a diverse background spanning industry leadership
roles, board service and investment banking.
"We are pleased to welcome Erik to Akebia as he brings proven
leadership experience across a broad range of critical functions.
He will be an important addition to our experienced leadership
team," said John P. Butler, Chief
Executive Officer of Akebia. "We are executing the Vafseo®
(vadadustat) Tablets launch from a solid financial position. Erik's
ability to manage all aspects of corporate finance, as well as his
track record in leading corporate development and strategic
transactions, we believe will enable us to create significant value
for our stakeholders."
Mr. Ostrowski joins Akebia from Avrobio, where he served as
President, Interim Chief Executive Officer and Chief Financial
Officer, leading the execution of its merger with Tectonic
Therapeutic. Prior to Avrobio, Mr. Ostrowski was Chief Financial
Officer of Summit Therapeutics where he led its initial public
offering on Nasdaq. He was recently Chair of the Audit Committee of
the Board of Directors of Faron Pharmaceuticals. Mr. Ostrowski also
spent over ten years in investment banking including at Leerink
Partners and Robertson Stephens. Mr. Ostrowski earned his
bachelor's degree in accounting and economics from Babson College and an MBA from the University of Chicago Booth School of Business.
"I am incredibly excited to join the Akebia team during this
transformational time for the company," said Mr. Ostrowski. "With
its new product launch, established revenue-generating business and
promising pipeline, Akebia is well-positioned for growth, and I
look forward to contributing to its future success."
About Akebia Therapeutics
Akebia Therapeutics, Inc. is
a fully integrated biopharmaceutical company with the purpose to
better the lives of people impacted by kidney disease. Akebia was
founded in 2007 and is headquartered in Cambridge, Massachusetts. For more
information, please visit our website at www.akebia.com, which does
not form a part of this release.
Forward-Looking Statements
Statements in this press
release regarding Akebia Therapeutics, Inc.'s ("Akebia's")
strategy, plans, prospects, expectations, beliefs, intentions and
goals are forward-looking statements within the meaning of the U.S.
Private Securities Litigation Reform Act of 1995, as amended, and
include, but are not limited to, statements regarding: Akebia's
execution of the Vafseo (vadadustat) Tablets launch from a solid
financial position, including its belief about its ability to
create significant value for its stakeholders; Akebia's promising
pipeline and that it is well-positioned for growth. The terms
"intend," "believe," "plan," "goal," "potential," "anticipate,
"estimate," "expect," "future," "will," "continue," derivatives of
these words, and similar references are intended to identify
forward-looking statements, although not all forward-looking
statements contain these identifying words. Actual results,
performance or experience may differ materially from those
expressed or implied by any forward-looking statement as a result
of various risks, uncertainties and other factors, including, but
not limited to, risks associated with: whether Vafseo will be
commercially available when expected; the potential demand and
market potential and acceptance of, as well as coverage and
reimbursement related to, Auryxia® and Vafseo, including estimates
regarding the potential market opportunity; the competitive
landscape for Auryxia and Vafseo, including potential generic
entrants; the ability of Akebia to attract and retain qualified
personnel; Akebia's ability to implement cost avoidance measures
and reduce operating expenses; decisions made by health
authorities, such as the FDA, with respect to regulatory filings;
the potential therapeutic benefits, safety profile, and
effectiveness of Vafseo; the results of preclinical and clinical
research; the direct or indirect impact of the COVID-19 pandemic on
the markets and communities in which Akebia and its partners,
collaborators, vendors and customers operate; manufacturing, supply
chain and quality matters and any recalls, write-downs, impairments
or other related consequences or potential consequences; and early
termination of any of Akebia's collaborations. Other risks and
uncertainties include those identified under the heading "Risk
Factors" in Akebia's Quarterly Report on Form 10-Q for the quarter
ended March 31, 2024, and other
filings that Akebia may make with the U.S. Securities and Exchange
Commission in the future. These forward-looking statements (except
as otherwise noted) speak only as of the date of this press
release, and, except as required by law, Akebia does not undertake,
and specifically disclaims, any obligation to update any
forward-looking statements contained in this press release.
Akebia Therapeutics® and Vafseo® are registered trademarks
of Akebia Therapeutics, Inc. and its affiliates.
Akebia Therapeutics Contact
Mercedes Carrasco
mcarrasco@akebia.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/akebia-therapeutics-appoints-erik-ostrowski-as-chief-financial-officer-and-chief-business-officer-302180302.html
SOURCE Akebia Therapeutics, Inc.